Medical device company Endra Life Sciences (NDRA) wants to sell 2 million shares at an expected price of $5.50 per share to raise $11 million in its IPO.
The company is developing enhanced ultrasound technologies that promise to expand the range of treatment options for a variety of indications.
While Endra has a one-year collaboration agreement with GE Healthcare, the long regulatory path ahead is fraught with potentially expensive delays, both in Europe and the U.S.
My opinion is NEUTRAL on the IPO.
Best Medical Stocks For 2018: Biogen Idec Inc(BIIB)
- [By WWW.THESTREET.COM]
Breakups have the potential to create a lot of value. Just look at what Biogen (BIIB) did with its hemophilia franchise. Spun out as Bioverativ (BIVV) , shares started trading earlier this year. The stock has climbed some 23% on seemingly no news, Cramer noted.
- [By Todd Campbell]
A new and highly anticipated study byCelgene Corp. (NASDAQ:CELG) shows that its promising multiple sclerosis drug could soon reshape the $19 billion multiple sclerosis market. On Friday, management reported that ozanimod met its primary endpoint for reducing MS relapses better than Biogen Inc.’s (NASDAQ:BIIB) Avonex, and importantly, it did so without any new safety risks.
- [By Brian Orelli]
While that’s fine for clinical trials, it may make it difficult for Ionis’ drugs to compete with drugs that work as well but don’t have side effects that need to be monitored. Of course, for Spinraza, which Biogen (NASDAQ:BIIB) and Ionis recently got approved for spinal muscular atrophy, side effects aren’t an issue because there aren’t any other treatment options at the moment.
- [By George Budwell]
Shares of theDanish drugmaker Forward Pharma A/S (NASDAQ:FWP) gained 48.2% yesterday as the result of a settlement and licensing deal with Biogen (NASDAQ:BIIB)involving an ongoing patent dispute over the multiple sclerosis drug Tecfidera. Per the terms of the deal, Biogen will fork overa non-refundable$1.25 billion licensing fee, and possibly pay 10% to 20% royalties on Tecfidera’snet sales to Forward starting in 2021.
Best Medical Stocks For 2018: Treehouse Foods, Inc.(THS)
- [By WWW.THESTREET.COM]
In the Lightning Round, Cramer was bullish on Treehouse Foods (THS) , TG Therapeutics (TGTX) , Kinder Morgan (KMI) , Magellan Midstream Partners (MMP) , Chesapeake Energy (CHK) and Arconic (ARNC) .
Best Medical Stocks For 2018: Delta Technology Holdings Limited(DELT)
- [By Jim Robertson]
On Wednesday, our Under the Radar Moversnewsletter suggested going long on small capChinese chemical stock Delta Technology Holdings Ltd(NASDAQ: DELT):
Best Medical Stocks For 2018: Medical Marijuana, Inc. (MJNA)
- [By Sean Williams]
This rapid growth in legal pot has create quite the demand for marijuana stocks. The seven largest marijuana stocks by market cap have all put on a show over the past couple of years. Here are those seven “green giants” listed with their market caps as of March 17, 2017, along with their trailing one-year total returns.
GW Pharmaceuticals (NASDAQ:GWPH): $3.0 billion, up 64% Canopy Growth Corp. (NASDAQOTH:TWMJF): $904 million, up 259% Aphria (NASDAQOTH:APHQF) $440 million, up 381% Aurora Cannabis (NASDAQOTH:ACBFF): $482 million, up 299% AXIM Biotechnologies (NASDAQOTH:AXIM): $562 million, up 1,720% Corbus Pharmaceuticals (NASDAQ:CRBP): $450 million, up 431% Medical Marijuana (NASDAQOTH:MJNA): $221 million, up 254%
As you can see, these are some hefty valuations — and some exceptionally strong moves higher on the heels of marijuana’s expansion. With the exception of GW Pharmaceuticals, every one of the largest marijuana stocks has at least tripled in value over the trailing 12 months, with cannabinoid-based drug developer AXIM Biotechnologies skyrocketing more than 1,700%!
- [By Jim Robertson]
When investors think of cannabinoid or marijuana stocks, they either think of better known stocks likeGW Pharmaceuticals PLC (NASDAQ: GWPH)and Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) that trade on bigger exchanges orCannabis Science Inc (OTCMKTS: CBIS) and Medical Marijuana Inc (OTCMKTS: MJNA) that are stilllisted on the OTC. However, there are other more indirect ways to invest in growing cannabinoid or marijuana acceptance.
- [By Keith Speights]
As increasingly more marijuana growers entered the market and more states allowed residents to legally grow marijuana, cannabis prices dropped throughout 2016. Wholesale marijuana prices late in the year were roughly half the levels of 12 months earlier. Will this trend continue — and possibly hurt leading marijuana stocks including Aphria (NASDAQOTH:APHQF),Aurora Cannabis (NASDAQOTH:ACBFF), Medical Marijuana,Inc.(NASDAQOTH:MJNA), and even GW Pharmaceuticals (NASDAQ:GWPH) in the process?
- [By Matthew Briar]
Look out Cannabis Science Inc (OTCMKTS:CBIS), and step aside Medical Marijuana Inc (OTCMKTS:MJNA). There’s a new cannabis name on the scene…. Algae Dynamics Corp. (OTCMKTS:ADYNF). It may not be known (or named) like its marijuana peers, but give it time. This small cap company has a very big idea, and it’s going to sprout soon.
Yes, Algae Dynamics is an algae company. It’s not just an algae company though.
Algae Dynamics is the owner of the proprietary BioSilo ™ process. BioSilo is a way of growing algae quickly and effectively…. a mix of an open-pond system and a photobioreactor, which is a light-driven approach to growing algae. It can be viewed as a “best of both worlds” approach, lowering the typical cost of algae farming, while the modular design makes it easy to maintain.
The company could go a lot of directions with the technology, Most of the tens of thousands of species of algae are rather flexible in how they can be purposed, and what they can become. Algae Dynamics is first focused on the development of two kinds of products though…. Chlorella, and Omega-3.
Chlorella is a type of microalgae that can be processed into a consumable powder by drying it until it takes a powder form, similar to coffee. Chlorella is rich in minerals, prebiotics, vitamins, and other nutritional substances. It can be added to a baked goods and a number of other products, or taken as a supplement on its own. Chlorella is used in over 1,000 products in the food and beverage markets. Algae Dynamics estimates the global Chlorella market was $210.3 million in 2014 and is expected to reach $265.5 million in 2018.
Despite a market for Chlorella in North America, there are no commercial North American producers of it.
Due to its health benefits, Omega-3 oil can be added to a very wide range of products. Consumers are increasingly aware of these benefits too, leading to substantial growth in the industry; health supplements compr
- [By Peter Graham]
A long term performance chart shows GW Pharmaceuticals PLC outperforming other small cap marijuana stocks like Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), Cannabis Science Inc (OTCMKTS: CBIS) and Medical Marijuana Inc (OTCMKTS: MJNA), but that outperformance has come withconsiderable volatility:
- [By SEEKINGALPHA.COM]
Recommendation #3 Worked Well – I also recommended that you “buy” any marijuana stocks you liked in late December and in anticipation of late December 2016 tax loss selling followed by a January effect increase in price-per-share or recovery. That is the topic of this article. I also had a few stock picks: (1) Cannabix Technologies (OTCPK:BLOZF) is up 10%, (2) Breathtec Biomed (OTCQB:BTHCF) is up 13%, (3) Bayport International (OTCPK:BAYP) is flat, though news might result in an increase by month end – this is a risky one, and (4) Medical Marijuana (OTCPK:MJNA) is up 6%.
Best Medical Stocks For 2018: Amgen Inc.(AMGN)
- [By Ben Levisohn]
What do I mean? Regeneron’s dropped 14% during the last three months, the result of a patent suit with Amgen(AMGN) over its anti-cholesterol drug Praluent, which a judge had set it wouldn’t be able to sell in the U.S.Then last night, there was finally good news: Ajudge ordered a stay, which would allow Regeneron to sell Praluent, and resulted in a 2% pop in its shares last night after the market close. But then Regeneron reported earnings, and while profits of $3.04 cents a share metthe Street consensus, Regeneron missed on sales and offered disappointing guidance. That caused Regeneron shares to sink 2.1% in pre-open trading.
- [By Keith Speights]
Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY), and Amgen (NASDAQ:AMGN) stand out as three of the most likely suitors for Incyte. Here’s why these big drugmakers could be interested in making a significant acquisition.
- [By Ben Levisohn]
Regeneron Pharmaceuticals (REGN) tumbled to the bottom of the S&P 500 today after a judge said the company could be forced to stop selling an anti-cholesterol drug due to violating an Amgen (AMGN) patent.